489 related articles for article (PubMed ID: 17673480)
1. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.
Yu HH; Wang LC; Lee JH; Lee CC; Yang YH; Chiang BL
Rheumatology (Oxford); 2007 Sep; 46(9):1492-4. PubMed ID: 17673480
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
4. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
5. Recurrent major infections in juvenile-onset systemic lupus erythematosus--a close link with long-term disease damage.
Lee PP; Lee TL; Ho MH; Wong WH; Lau YL
Rheumatology (Oxford); 2007 Aug; 46(8):1290-6. PubMed ID: 17522097
[TBL] [Abstract][Full Text] [Related]
6. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual.
Bertoli AM; Vilá LM; Apte M; Fessler BJ; Bastian HM; Reveille JD; Alarcón GS;
Rheumatology (Oxford); 2007 Sep; 46(9):1471-6. PubMed ID: 17650522
[TBL] [Abstract][Full Text] [Related]
10. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
11. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
[TBL] [Abstract][Full Text] [Related]
12. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus.
Fragoso-Loyo HE; Sánchez-Guerrero J
J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970
[TBL] [Abstract][Full Text] [Related]
13. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
14. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.
Ainiala H; Hietaharju A; Dastidar P; Loukkola J; Lehtimäki T; Peltola J; Korpela M; Heinonen T; Nikkari ST
Arthritis Rheum; 2004 Mar; 50(3):858-65. PubMed ID: 15022328
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients.
Zhou HQ; Zhang FC; Tian XP; Leng XM; Lu JJ; Zhao Y; Tang FL; Zhang X; Zeng XF; Zhang ZL; Zhang W; Dong Y
Lupus; 2008 Feb; 17(2):93-9. PubMed ID: 18250131
[TBL] [Abstract][Full Text] [Related]
16. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
17. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus.
Ng WL; Chu CM; Wu AK; Cheng VC; Yuen KY
QJM; 2006 Jan; 99(1):37-47. PubMed ID: 16371405
[TBL] [Abstract][Full Text] [Related]
18. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
19. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
20. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]